Predictive Molecular Blood Biomarkers in Non-Small Cell Lung Cancer

authors:

avatar Abdolreza Mohamadnia ORCID 1 , * , avatar Mohammad Hoseine Talischi 2 , avatar Minoo Mahmoodi 2 , avatar Naghmeh Bahrami 3 , avatar Abdollah Farhadinasab 4

Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences(SBMU), Tehran, Iran
Department of Biology, Faculty of Basic Sciences, Hamedan Branch, Islamic Azad University, Hamedan, Iran
Craniomaxillofacial Research Center, TUMS, Tehran, Iran
Behavioral Sciences Research Center, Taleghani Hospital, SBMU, Tehran, Iran

how to cite: Mohamadnia A, Talischi M H, Mahmoodi M, Bahrami N, Farhadinasab A. Predictive Molecular Blood Biomarkers in Non-Small Cell Lung Cancer. J Cell Mol Anesth. 2022;7(2):e151418. https://doi.org/10.5812/jcma-151418.

Abstract

Background: Lung cancer is characterized by the uncontrolled growth of cells in the lung tissue. The purpose of the present study was to investigate the expression of MUC1 mRNA and CK19 mRNA biomarkers in patients with non-small-cell lung carcinoma (NSCLC).
Materials and Methods: In this case-control research, thirty samples of cancer blood, thirty samples of cancer tissue, and the same number of healthy samples were prepared. Samples were collected and RNA was extracted, then cDNA was made and gene expression was measured using Real-Time PCR.
Results: Among non-small-cell lung carcinoma patients, the MUC1 mRNA marker was positive for 19 individuals while in the healthy group, it was reported positive in 5 out of 30 individuals. In the patients' group, the CK19 mRNA marker was positive for 16 individuals while in the healthy group, in 6 out of 30 individuals.
Conclusion: The MUC1 mRNA and CK19 mRNA as lung cancer tumor markers were reliable and sensitive; however, further studies are recommended

References

  • 1.

    References are in the PDF file of the article.